Loading
Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed). The dividing line shapes ovarian and small-cell lung cancer treatment.
In ovarian cancer, relapse ≥6 months after platinum is treated with another platinum doublet, often followed by PARP maintenance, and secondary cytoreduction may help; relapse within 6 months (resistant) or during treatment (refractory) has response rates under 15% to single agents and is where mirvetuximab (folate receptor alpha), and trials of new ADCs, are focused. Small-cell lung cancer uses a 90-day cut-off for platinum-etoposide rechallenge. 'Platinum-ineligible' (kidney function, hearing, neuropathy) defines a treatment pathway in bladder cancer. Platinum-resistance mechanisms include restored homologous recombination (BRCA reversion) and drug efflux.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Cisplatin.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Folate receptor alpha expression (FRα-positive, PS2+ >= 75%), BRCA reversion mutations, HRD-positive (genomic instability score), Homologous recombination deficiency (HRD).
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin.
Shares HRD-positive (genomic instability score), Homologous recombination deficiency (HRD), Platinum agents, Cisplatin.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Platinum agents, Cisplatin.
Shares Extensive-stage small-cell lung cancer, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares HRD-positive (genomic instability score), Homologous recombination deficiency (HRD), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma.
Shares Extensive-stage small-cell lung cancer, Platinum agents, Cisplatin, Carboplatin.